Abstract
Melanoma is a highly invasive and metastatic cancer, with high rates of mortality and chemoresistance. The MAPK pathway is constitutively activated, and there are already available powerful target-specific chemotherapeutics, such as BRAF inhibitors (Vemurafenib and Dabrafenib). However, resistance to BRAF inhibitors is observed after about 7 months of treatment, primarily because of the h…